The Economics of Value-Based Care in Healthcare Transactions

The distinction between GAAP treatment and the underlying transaction economics in value-based care arrangements can create a disconnect that has a real impact on diligence and deal treatment.

The transaction issue

Value-based care arrangements, in which payment amounts are tied to results for patients, are becoming more common in healthcare transactions. The priority question a buyer should ask when performing diligence on a target with such arrangements is “What are the economics of the arrangements?”

Those performing diligence should guard against using broad assumptions that either oversimplify the economics or overstate the complexity of such arrangements. Rather, the diligence conclusion should be grounded on specific contract mechanics, risk allocation, settlement timing, retained economics, and transaction implications.

Differences between GAAP treatment and transaction economics

In value-based care diligence, deal teams often ask a narrow question: Do the financial statements follow generally accepted accounting principles (GAAP)?

The answer is significant, but it is not where the questioning should end.

GAAP addresses recognition, measurement, presentation, and disclosure based on the applicable facts and circumstances. Transaction diligence then uses those conclusions to evaluate the related cash timing, retained economics, recurrence, and deal treatment – that is, the deal economics.

Transaction diligence should answer additional questions:

• Are the economics of the arrangements driven by cost performance, quality, attribution, or benchmark changes?
• Are the arrangements recurring, unusual, or settlement driven?
• When will the cash flows of the arrangements be realized?
• Are the arrangements presently reflected in the financial statements based on preliminary information or final settlement data?
• Are the amounts recognized for the arrangements presented gross or net of medical costs, quality incentives, withholds, offsets, or distributions?
• Does the target retain the economics of the arrangement?
• Who bears downside, recoupment, or repayment exposure?
• Do capitation or premium-pool payments function as advances, medical costs, or settlement offsets?
• Are the amounts recognized for the arrangements expected to affect adjusted EBITDA, net working capital, debt-like items, indemnity, or a separate purchase agreement true-up?

GAAP might tell the buyer what it needs to know about financial reporting. Transaction diligence must answer questions about economics.

The three views buyers and sellers need to reconcile

A practical value-based care diligence process should reconcile three views: the GAAP view, the contract view, and the economic view.

The diligence team’s role is to bridge these views. That bridge should connect the arrangement to the performance period, GAAP recording period, cash settlement date, gross amount, cost-of-care components, distributions, retained amount, open receivable or liability, and proposed transaction treatment.

The goal is to make value-based care economics transparent.

Where diligence often breaks down

Several issues tend to create confusion in healthcare transactions involving value-based care arrangements. Each is a point where the GAAP, contract, and economic views can tell different stories – and where a bridge connecting them matters most.

Gross economics versus net GAAP amounts

Even a correct net GAAP amount might be analytically incomplete if it obscures medical cost exposure, benchmark performance, settlement timing, or downstream distributions. Conversely, gross presentation could be misleading if it implies the target owns activity that legally or economically belongs to another entity.

For quality of earnings (QoE) purposes, the question is not simply whether GAAP requires gross or net presentation. The question is whether the reported amount allows a buyer to understand adjusted EBITDA, cash conversion, medical cost exposure, retained economics, and the underlying drivers of contract performance.

As a practical rule, the diligence analysis should show gross economics when the gross activity helps explain the target’s risk, margin, cash flow, EBITDA, or underlying drivers of contract performance. It should show net economics when only the retained amount is attributable to the target.

In either case, the analysis should bridge back to retained economics. A supplemental gross QoE view can help buyers understand performance, comparability, and risk, but it should not be presented as GAAP revenue unless the accounting analysis supports that presentation.

Capitation payments and advanced cash activity

In some arrangements, depending on the contract terms and settlement mechanics, capitation payments might function economically as an advance against anticipated surplus or savings. This can arise in certain value-based care contracts where capitation is treated as a medical cost or settlement offset in the performance calculation. Practically, these payments might provide working capital or operating cash flow before final settlement, which is why diligence should reconcile the advanced cash activity to the ultimate contract economics.

The distinction between advanced cash activity and the contract economics matters because the cash receipt might not represent final retained economics. QoE providers should understand the contract terms and perform the necessary reconciliations to determine whether capitation represents earned revenue, a medical cost, an advance against surplus, a settlement offset, or a potential recoupment exposure. If an organization is in a deficit position, future surplus may first be applied against prior-period deficits or advanced cash activity before creating incremental retained cash flow, which can affect cash conversion, retained economics, and purchase agreement treatment.

Downside-only contracts presented gross for comparability

Diligence should evaluate contracts across a portfolio on a consistent basis, even when their risk structures differ. For example, a company might have several contracts with medical expense ratio or medical loss ratio performance presented on a gross premium and medical cost basis, while one material contract primarily is downside-only. Presenting the downside-only contract only on a net basis, even if appropriate under the applicable accounting analysis, might prevent the buyer from comparing medical cost performance across the portfolio.

In that situation, a QoE provider may present a supplemental view of gross premium (or benchmark) and cost of care so the contract can be compared with the rest of the portfolio while clearly labeling the contract as downside-only and reconciling the analysis back to GAAP presentation and target-retained economics.

The goal is comparability, not implying upside participation, gross revenue ownership, or incremental EBITDA that the target does not have under the contract.

Pre-close performance that settles after close

Value-based care settlements often lag the performance period. A shared savings receivable, shared loss liability, quality withhold, capitation reconciliation, or payer recoupment may be recorded in one period, settle in another period, and relate economically to a third period.

That timing disconnect can create purchase agreement issues. If pre-close performance generates a post-close cash receipt, who owns the benefit? If pre-close performance generates a post-close repayment obligation, who bears the cost? Should the post-close settlement amount be included in working capital, treated as a debt-like item, carved out, indemnified, or subject to a separate true-up?

These questions are easier to resolve before closing than after the payer or Centers for Medicare & Medicaid Services (CMS) settlement is finalized.

What a good economics bridge should address

Each of these issues points to the same need: a practical bridge connecting the GAAP, contract, and economic views. For each material arrangement, that bridge should answer several questions.

A complete bridge also should reconcile to the general ledger, settlement statements, payer or CMS reports, bank activity, management estimates, and subsequent cash receipts or payments.

When the bridge is missing, buyers might struggle to underwrite value-based care economics. When the bridge is clear, complexity becomes more manageable.

Going forward: Build bridges to clarify transactions

Buyers in transactions involving value-based care arrangements should not oversimplify or overreact to them. When bridges are built from GAAP results to deal economics, transactions become more transparent and analyzable sources of risk and opportunity.